A method for synthesizing cabozantinib and its intermediates

By optimizing the cabotinib synthesis method, 4-((6,7-dimethyl-quinoline-4-yl)oxy) was used to replace benzene and N-p-fluorophenyl-1,1-dicarboxamide group were used to replace benzene with N-p-fluorophenyl-1,1-dicarboxamide group The reaction of cyclopropane solves the problems of harsh process conditions and low yields in the prior art, and achieves efficient and simple synthesis of cabotinib, which is suitable for industrial production.

CN112390749BActive Publication Date: 2024-12-03LUNAN PHARMA GROUP CORPORATION
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN201910763341.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-08-19
Publication Date
2024-12-03
Estimated Expiration
2039-08-19

AI Technical Summary

Technical Problem

The existing cabotinib synthesis method has harsh process conditions, many by-products, difficult to purify, low yield, and is not suitable for industrial production.

Method used

4-((6,7-dimethyl-quinoline-4-yl)oxy) substituted benzene and N-p-fluorophenyl-1,1-dicarboxamide cyclopropane under basic conditions. By optimizing catalyst and solvent selection, simplifying the process flow, avoiding the use of sulfoxide, and improving product purity and yield.

Benefits of technology

The high yield of cabotinib (up to 92.6%) and high purity industrial production has been achieved, reducing production costs and simplifying the operation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002171079120000011
    Figure BDA0002171079120000011
  • Figure BDA0002171079120000021
    Figure BDA0002171079120000021
  • Figure BDA0002171079120000031
    Figure BDA0002171079120000031
Patent Text Reader

Abstract

The present invention provides a method for synthesizing cabozantinib and an intermediate thereof, and belongs to the field of pharmaceutical chemistry. The present invention adopts cyclopropane-1,1-dicarboxylic acid amide as a key intermediate, and reacts with substituted fluorobenzene and 4-((6,7-dimethyl-quinoline-4-yl)oxy) substituted benzene to obtain product cabozantinib. The present invention effectively avoids the generation of by-products, improves the yield of preparing cabozantinib and the utilization rate of raw materials, saves production costs, and is more suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and in particular relates to a method for synthesizing cabozantinib and an intermediate thereof. Background Art

[0002] The chemical name of Cabozantinib is cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]amide (4-fluoro-phenyl)amide, and its molecular formula is C 28 H 24 FN3O5, relative molecular weight is 502, density is 1.396g / cm 3 . It is a quinolyloxydiphenylcyclopropane dicarboxamide derivative developed by Exelixis, USA. It is a multi-target (MET, VEGFR1, VEGFR2, VEGFR3, RET, ROS1, KITAXL, NTRK) anticancer drug that effectively inhibits the growth and metastasis of cancer cells. In 2012, it was approved by the US FDA for the indications of relapsed and refractory advanced medullary thyroid cancer and advanced renal cancer that failed to be treated with Sutent. In the clinical trial stage, it also has indications for liver cancer, ovarian cancer, intestinal cancer, prostate cancer, breast cancer, etc. 76% of patients had partial or complete tumor atrophy after receiving cabozantinib treatment, because it can block two signal transduction pathways for tumor proliferation. The most common adverse reactions are bleeding, diarrhea, gastrointestinal perforation and fistula, reversible posterior white matter syndrome, and potential harm to the fetus.

[0003] The molecular structure of cabozantinib is composed of substituted quinoline, 4-oxyphenylimine, 1,1-diacylcyclopropane and 4-fluorophenylimine. The structural formula is as follows:

[0004]

[0005] In patent WO2005030140A2, 6,7-dimethoxy-4-hydroxyquinoline and 1,1-cyclopropyl dicarboxylic acid are used as starting materials, 6,7-dimethoxy-4-hydroxyquinoline is reacted with trifluoromethanesulfonyl chloride to obtain an esterification product, 1,1-cyclopropyl dicarboxylic acid is reacted with p-fluoroaniline and p-hydroxyaniline to obtain an amide product (wherein 1,1-cyclopropyl dicarboxylic acid and p-fluoroaniline generate 1-(4-fluorophenyl)carbamoylcyclopropanecarboxylic acid, with a yield of 65.18%), and then the amide product and the esterification product are condensed at high temperature to obtain cabozantinib. This method has harsh process conditions, a large number of by-products, is difficult to purify, and is difficult to obtain high-quality products. The yield is low and is not conducive to industrial production. The synthetic route is as follows:

[0006]

[0007] The document "Synthesis of (S)-Malate Cabozantinib" (authors Chen Zhuo, Yu Gang, Zhang Qingwen, Chinese Journal of Pharmaceuticals 2014, 45(5)) provides a method for preparing cabozantinib: 2-nitro-4,5-dimethoxy-acetophenone (2) is used as a raw material, and 5% palladium carbon is catalytically hydrogenated at normal pressure to obtain 2-amino-4,5-dimethoxyacetophenone (3), (3) is cyclized with ethyl formate in the presence of sodium methoxide to obtain 4, 4 is chlorinated with phosphorus oxychloride to obtain 4-chloro-6,7-dimethoxyquinoline (5), (5) and 4-aminophenol are condensed in dimethyl sulfoxide with sodium hydroxide as an acid-binding agent to obtain (6), and (6) is condensed with (8) to form a salt to obtain 1. Among them, 1-[(4-fluorophenyl)carbamoyl]cyclopropanecarboxylic acid (8) is prepared from (7) and p-fluoroaniline with a yield of 66%; (6) and (8) are condensed and salted to obtain 1 with a yield of 93%. The total yield of the two steps is 61.38%. The synthetic route is as follows:

[0008]

[0009] Chinese patent CN201710513105.0 provides a method for preparing cabozantinib, wherein 1,1-cyclopropyldicarboxylic acid is added to a reaction bottle, thionyl chloride is added, and the mixture is slowly heated under stirring to react. After the reaction is completed, excess thionyl chloride is evaporated under reduced pressure, tetrahydrofuran or N,N-dimethylformamide solvent and an acid binding agent are added, the mixture is stirred and cooled, 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline is dissolved in tetrahydrofuran, and the mixture is slowly added dropwise to the reaction mixture. In the system, continue to stir the reaction; TLC detection until 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline reacts completely, heat up, slowly drop p-fluoroaniline diluted with tetrahydrofuran; heat up and continue to stir the reaction, change to a distillation device, and evaporate tetrahydrofuran or N, N-dimethylformamide solvent under reduced pressure; cool down, add an acid-binding agent to adjust the pH to 7-8, then slowly drop pure water, stir and crystallize; filter, wash, and dry to obtain a crude product of cabozantinib; the total yield is 64%. The synthetic route is as follows:

[0010]

[0011] Chinese patent CN201610505245.9 discloses a method for synthesizing cabozantinib: 1) 1,1-cyclopropyldicarboxylic acid is subjected to chlorination reaction with a chlorinating agent to obtain an intermediate of formula II, and the intermediate of formula II is condensed with 4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline to obtain an intermediate of formula III, namely N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-1-formamide-cyclopropyl-1-carboxylic acid; step 2) the intermediate of formula III is condensed with 4-fluoroaniline in the presence of a condensing agent and a base to obtain cabozantinib, with a total yield of up to 64.4% and a minimum of 19.56%.

[0012] Most of the prior art uses 1,1-cyclopropyl dicarboxylic acid as starting material, and then further prepares through chlorination and condensation, or further prepares through direct condensation of 1,1-cyclopropyl dicarboxylic acid. The raw materials used for preparation are expensive and the chemical properties are more active and difficult to store in large quantities. In the condensation process, thionyl chloride is used to easily cause equipment corrosion, and the chemical properties of acyl chloride are more active, causing the odor on the scene to be heavier, which is not conducive to large-scale industrial production. Moreover, the carboxyl groups on both sides of 1,1-cyclopropyl dicarboxylic acid and chlorination are all more active, and impurities are easily generated in the reaction process, resulting in lower yield and purity.

[0013] Chinese patent CN201210374723.9 provides a method for preparing Cabozantinib, wherein 1,1-cyclopropanedicarboxylic acid ethyl ester (2) is subjected to alkaline monohydrolysis at low temperature, and 1-(ethoxycarbonyl)cyclopropanecarboxylic acid (3) is obtained by acid extraction, and dichlorothionyl chloride or oxalyl chloride is added dropwise to (3) at low temperature to obtain an acyl chloride, which is then condensed with 4-aminophenol to obtain 1-((4-hydroxyphenyl)carbamoyl)cyclopropanecarboxylic acid ethyl ester (4), and 4 is reacted with 4-chloro-6,7-dimethoxyquinoline at high temperature to obtain 1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropanecarboxylic acid ethyl ester (5) after purification, and the ethyl group of (5) is hydrolyzed and then condensed with p-fluoroaniline to obtain the target product 1, with a total yield of 8.3%. This route uses 1,1-cyclopropanedicarboxylic acid diethyl ester as the raw material, avoiding the situation when using 1,1-cyclopropyl dicarboxylic acid, where the carboxyl groups on both sides and the chlorination are relatively active and easy to produce impurities. However, the patent adds two steps of hydrolysis process, and the overall yield is low. The synthetic route is as follows:

[0014]

[0015] In summary, there are still many problems with the existing methods for synthesizing cabozantinib. It is still a problem that needs to be solved to find a synthetic route for cabozantinib that is suitable for industrial production and has mild reaction conditions, simple operation process, high product yield, high purity, and low production cost. Summary of the invention

[0016] The purpose of the present invention is to provide a method for synthesizing cabozantinib and its intermediates in view of the problems existing in the prior art.

[0017] The present invention adopts the following technical solutions:

[0018] (1) A method for synthesizing cabozantinib, wherein a compound of formula V, 4-((6,7-dimethyl-quinolin-4-yl)oxy)substituted benzene, and a compound of formula IV, N-p-fluorophenyl-1,1-dicarboxamidocyclopropane, are reacted to obtain a compound of formula VI, cabozantinib, as shown in the following reaction formula:

[0019]

[0020] Wherein R is one of Cl, Br, I, NH2 and B(OH)2.

[0021] A method for synthesizing the above-mentioned cabozantinib specifically comprises the following steps:

[0022] The compound of formula V, 4-((6,7-dimethyl-quinolin-4-yl)oxy)substituted benzene and the compound of formula IV, N-p-fluorophenyl-1,1-dicarboxamidocyclopropane, are dissolved in an organic solvent, and then a base and a catalyst are added in sequence, and the mixture is heated under reflux for reaction. After the reaction is completed, post-treatment is performed to obtain the compound of formula VI, cabozantinib.

[0023] Preferably, the molar ratio of the compound of formula V to the compound of formula IV is 1:0.8 to 1:1.

[0024] Preferably, the mass of the catalyst used is 10% to 100% of the mass of the compound of formula V, and further preferably, the mass of the catalyst used is 40%.

[0025] Preferably, the molar amount of the base is 1 to 4 times the molar amount of the compound of formula V.

[0026] Preferably, the volume amount of the organic solvent is 5 to 10 times the total mass of the input materials, the compound of formula V, the compound of formula IV, the base and the catalyst, wherein the volume is measured in ml and the mass is measured in g.

[0027] Preferably, when R in the above reaction formula is NH2: no alkali is needed; the organic solvent is one or a combination of N,N-dimethylformamide, dimethyl sulfoxide, toluene, and xylene, and N,N-dimethylformamide is further preferred; the catalyst is one or a combination of Fe2(SO4)3, FeCl3·6H2O, and Fe(NO3)3·9H2O, and Fe(NO3)3·9H2O is further preferred.

[0028] Preferably, when R is B(OH)2 in the above reaction formula: the organic solvent is one of methanol, acetonitrile, and dichloromethane or a combination thereof, and methanol is further preferred; the base used is one of pyridine, triethylamine, and potassium carbonate or a combination thereof, and potassium carbonate is further preferred; the catalyst is one of Cu(OAc)2·H2O, CuSO4·5H2O, Cu2O, CuCl, and CuI or a combination thereof, and Cu(OAc)2·H2O is further preferred.

[0029] Preferably, when R in the above reaction formula is Cl, Br, or I: the organic solvent is one or a combination of N,N-dimethylformamide, dimethyl sulfoxide, and toluene, and toluene is further preferred; the base used is one or a combination of cesium carbonate, sodium carbonate, and potassium carbonate, and potassium carbonate is further preferred; the catalyst is one or a combination of CuSO4·5H2O, Cu2O, and Cu / SiO2, and CuSO4·5H2O is further preferred.

[0030] Further preferably, when R is NH2 or B(OH)2, the heating reflux reaction time is 5 to 10 h, and when R is Cl, Br or I, the heating reflux reaction time is 10 to 15 h.

[0031] In a preferred embodiment, after the reaction is completed, the post-treatment step includes: cooling the reaction solution to room temperature, adding purified water, then extracting with an extractant, combining the organic phases and spinning them to dryness, beating with a beating liquid, filtering, and drying to obtain the compound of formula VI, cabozantinib.

[0032] Further preferably, the extractant is ethyl acetate.

[0033] Further preferably, the slurry is a mixture of isopropanol and tetrahydrofuran, wherein the volume ratio of isopropanol to tetrahydrofuran is 3:1.

[0034] (2) A method for synthesizing a compound of formula IV, wherein a compound of formula II and a compound of formula III are dissolved in an organic solvent and reacted under alkaline conditions and a catalyst to obtain a compound of formula IV. The synthetic route is as follows:

[0035]

[0036] Wherein R is Cl, Br, I, NH2, B(OH)2.

[0037] A method for synthesizing the compound of formula IV comprises the following steps:

[0038] The compound 1,1-dicarboxamidocyclopropane of formula II and the substituted fluorobenzene of formula III are dissolved in an organic solvent, and then a base and a catalyst are added in sequence, and the mixture is heated under reflux for reaction. After the reaction is completed, post-treatment is performed to obtain the compound N-p-fluorophenyl-1,1-dicarboxamidocyclopropane of formula IV.

[0039] Preferably, the molar ratio of the compound of formula II to the compound of formula III is 1:0.8 to 1:1.

[0040] Preferably, the mass of the catalyst used is 10% to 100% of the mass of the compound of formula II, and further preferably, the mass of the catalyst used is 40%.

[0041] Preferably, the molar amount of the base is 1 to 4 times the molar amount of the compound of formula II.

[0042] Preferably, the volume amount of the organic solvent is 5 to 10 times the total mass of the compound of formula II, the compound of formula III, the base and the catalyst, wherein the volume is measured in ml and the mass is measured in g.

[0043] Preferably, when R in the above reaction formula is NH2: no alkali is needed; the organic solvent is one or a combination of N,N-dimethylformamide, dimethyl sulfoxide, toluene, and xylene, and dimethylformamide is further preferred; the catalyst is one or a combination of Fe2(SO4)3, FeCl3·6H2O, and Fe(NO3)3·9H2O, and Fe(NO3)3·9H2O is further preferred.

[0044] Preferably, when R in the above reaction formula is B(OH)2: the organic solvent is one of methanol, acetonitrile, and dichloromethane or a combination thereof, and methanol is more preferably used; the base used is one of pyridine, triethylamine, and potassium carbonate or a combination thereof, and potassium carbonate is more preferably used; the catalyst is one of Cu(OAc)2·H2O, CuSO4·5H2O, Cu2O, CuCl, and CuI or a combination thereof, and Cu(OAc)2·H2O is more preferably used;

[0045] Preferably, when R in the above reaction formula is Cl, Br, or I: the organic solvent is one of dimethylformamide, dimethyl sulfoxide, and toluene, or a combination thereof, and toluene is further preferred; the base used is one of cesium carbonate, sodium carbonate, and potassium carbonate, or a combination thereof, and potassium carbonate is further preferred; the catalyst is one of CuSO4·5H2O, Cu2O, and Cu / SiO2, or a combination thereof, and CuSO4·5H2O is further preferred.

[0046] Further preferably, when R is NH2 or B(OH)2, the heating reflux reaction time is 4 to 12 h, and when R is Cl, Br or I, the heating reflux reaction time is 8 to 16 h.

[0047] In a preferred embodiment, after the reaction is completed, the post-treatment step includes: cooling the reaction solution to room temperature, adding purified water, then extracting with an extractant, combining the organic phases and spinning them to dryness, beating with a beating liquid, filtering, and drying to obtain compound IV N-p-fluorophenyl-1,1-dicarboxamidocyclopropane.

[0048] Further preferably, the extractant is ethyl acetate.

[0049] Further preferably, the slurry is a mixture of isopropanol and tetrahydrofuran, wherein the volume ratio of isopropanol to tetrahydrofuran is 3:1.

[0050] (3) The present invention also provides a method for synthesizing the compound of formula II, which is obtained by hydrolyzing the compound of formula I in a hydrolysis system, and the reaction formula is as follows:

[0051]

[0052] A method for synthesizing the compound of formula II, comprising the following steps:

[0053] The compound of formula I is reacted in a hydrolysis system under controlled temperature, and the cyano group is hydrolyzed to amide. After the reaction is completed, the compound of formula II is obtained through post-treatment.

[0054] Preferably, the hydrolysis system is an alkali-organic system with H2O2 added, wherein the alkali is one of LiOH, NaOH, KOH, K2CO3, Na2CO3 or a combination thereof, more preferably KOH or K2CO3, and more preferably KOH. The organic solvent is one of dimethyl sulfoxide, ethanol, isopropanol, tert-butyl alcohol, tetrahydrofuran or a combination thereof, more preferably dimethyl sulfoxide. Further preferably, the volume of the organic solvent is 10 to 20 times the mass of the compound of formula I, wherein the volume is measured in ml and the mass is measured in g; the ratio of the amount of the alkali to the molar amount of formula I is 1:1 to 3, and the ratio of the amount of hydrogen peroxide to the molar amount of formula I is 1:1 to 8.

[0055] Preferably, the hydrolysis system can also be an alkali-CH2Cl2 phase transfer catalytic system, wherein the organic solvent is dichloromethane. The alkali is one of LiOH, NaOH, KOH, K2CO3, Na2CO3 or a combination thereof, more preferably KOH or K2CO3, more preferably KOH. The phase transfer catalyst is one of tetrabutylammonium hydrogen sulfate, 18 crown 6, 15 crown 5, cyclodextrin, benzyltriethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium chloride, trioctylmethylammonium chloride, dodecyltrimethylammonium chloride, tetradecyltrimethylammonium chloride or a combination thereof, more preferably tetrabutylammonium hydrogen sulfate. Further preferably, the volume of dichloromethane is 10 to 20 times the mass of the compound of formula I, wherein the volume is measured in ml and the mass is measured in g; the amount of alkali is 2 to 3 times the molar amount of the compound of formula I, and the amount of the phase transfer catalyst is 0.1 to 0.3 times the molar amount of the compound of formula I.

[0056] Preferably, the reaction temperature is 15 to 70°C, more preferably 60°C;

[0057] Preferably, the reaction time is 10 to 20 hours, more preferably 12 hours.

[0058] In a preferred embodiment, after the reaction is completed, the post-treatment step includes: washing the organic layer with water, drying with sodium sulfate and then spin-drying to obtain a white solid, slurrying with ethyl acetate, filtering, and drying to obtain the compound of formula II 1,1-dicarboxamidocyclopropane.

[0059] (4) In a preferred embodiment of the present invention, a method for synthesizing cabozantinib is provided, and the synthetic route is as follows:

[0060]

[0061] Wherein R is Cl, Br, I, NH2, B(OH)2.

[0062] In the above synthetic route, the compound of formula II is obtained by hydrolyzing the cyano group of the compound of formula I in a hydrolysis system;

[0063] In the above synthetic route, the compound of formula II is dissolved in an organic solvent and reacted with the compound of formula III under alkaline conditions and the action of a catalyst to obtain the compound of formula IV;

[0064] In the above synthetic route, the compound of formula IV is dissolved in an organic solvent and reacts with the compound of formula V under alkaline conditions and the action of a catalyst to obtain the compound of formula VI.

[0065] (5) The compound of formula V used in the present invention can be purchased on the market, or can be prepared by existing techniques, or can be prepared by the method provided by the present invention. The present invention provides a method for synthesizing the compound of formula V, and the synthetic route is as follows:

[0066]

[0067] Wherein X is Cl, Br or I, and R is one of Cl, Br, I, NH2, and B(OH)2;

[0068] The synthesis method of the compound of formula V specifically comprises the following steps:

[0069] Add 4-halogeno-6,7-dimethoxyquinoline compound of formula a, substituted phenol compound of formula b and base into an organic solution, heat to react, cool after the reaction is completed, and obtain compound of formula V through post-treatment.

[0070] Preferably, the molar equivalent ratio of the compound of formula a to the compound of formula b is 1:1 to 1:2.

[0071] Preferably, the molar amount of the base is 2 to 6 times the molar amount of the compound of formula a.

[0072] Preferably, the volume amount of the organic solvent is 8 to 10 times the total mass of the input compound of formula a, compound of formula b and base, wherein the volume is measured in ml and the mass is measured in g.

[0073] Preferably, the organic solvent is one of N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, diphenyl ether, chlorobenzene or a combination thereof, wherein N,N-dimethylformamide is preferred. The base is one of sodium methoxide, sodium ethoxide, potassium tert-butoxide, potassium carbonate, cesium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide or a combination thereof, wherein cesium carbonate is preferred.

[0074] Preferably, the post-treatment comprises the following steps: pouring the reaction solution after the reaction into a saturated sodium chloride aqueous solution or a saturated ammonium chloride aqueous solution, slurrying with a slurry liquid, filtering, and drying to obtain a 4-((6,7-dimethyl-quinolin-4-yl)oxy) substituted benzene compound of formula V; further preferably, the slurry liquid is one of ethyl acetate, butyl acetate, isopropyl acetate, or a combination thereof.

[0075] The present invention also provides the use of the above-mentioned compound of formula VI and compound of formula II in the preparation of cabozantinib drugs.

[0076] The cabozantinib synthesis method provided by the present invention is simple and easy to operate and control, and replaces the original material 1,1-cyclopropanedicarboxylic acid to avoid the use of dichlorothionyl. In addition, the present invention effectively avoids the generation of by-products by adopting 1,1-diformamidocyclopropane, thereby improving the yield of preparing cabozantinib and the utilization rate of raw materials, and the total yield is as high as 92.6%, thereby saving production costs and being more suitable for industrial production. DETAILED DESCRIPTION

[0077] The following specific examples are intended to enable those skilled in the art to more clearly understand and implement the present invention. They should not be considered as limiting the scope of the invention, but are merely exemplary and typical representations of the present invention. The solvent, reagent and raw material used in the present invention are all commercially available products. The modifications or optimizations made thereto on the basis of the present invention can be accomplished by those skilled in the art, so the modifications or optimizations made thereto without departing from the spirit of the present invention all belong to protection scope of the present invention.

[0078] (I) Preparation of 1,1-dicarboxamidocyclopropane (II)

[0079]

[0080] Example 1

[0081] 1,1-Dicyanocyclopropane (9.2 g, 0.1 mol) was dissolved in 156 ml of dichloromethane, and tetrabutylammonium hydrogen sulfate (6.8 g, 0.02 mol) and potassium hydroxide aqueous solution (containing 14.0 g, 0.25 mol of potassium hydroxide) were added. The temperature was controlled at 55°C-60°C and the reaction was carried out for 12 hours. After the reaction, the organic layer was washed with water. The organic layer was taken, dried with sodium sulfate (5.0 g) and then spin-dried to obtain a white solid. The solid was slurried with ethyl acetate (40 ml) to obtain 1,1-diformamidocyclopropane with a yield of 96.9% and a purity of 99.65%.

[0082] Example 2

[0083] 1,1-Dicyanocyclopropane (9.2 g, 0.1 mol) was dissolved in 184 ml of dichloromethane, and 18 crown 6 (7.9 g, 0.03 mol) and potassium carbonate aqueous solution (containing 41.4 g, 0.30 mol of potassium carbonate) were added. The temperature was controlled at 60°C-70°C and the reaction was carried out for 10 hours. After the reaction, the organic layer was washed with water. The organic layer was taken, dried with sodium sulfate (5.0 g) and then spin-dried to obtain a white solid. The solid was slurried with ethyl acetate (40 ml) to obtain 1,1-diformamidocyclopropane with a yield of 95.3% and a purity of 99.54%.

[0084] Example 3

[0085] 1,1-dicyanocyclopropane (9.2 g, 0.1 mol) was dissolved in 92 ml of dichloromethane, and α-cyclodextrin (9.7 g, 0.01 mol) and lithium hydroxide aqueous solution (containing 4.8 g, 0.20 mol of lithium hydroxide) were added. The temperature was controlled at 15°C-20°C and the reaction was carried out for 20 hours. After the reaction, the organic layer was washed with water. The organic layer was taken, dried with sodium sulfate (5.0 g) and then spin-dried to obtain a white solid. The solid was slurried with ethyl acetate (40 ml) to obtain 1,1-diformamidocyclopropane with a yield of 94.6% and a purity of 99.12%.

[0086] Example 4

[0087] 1,1-dicyanocyclopropane (9.2 g, 0.1 mol) was dissolved in 156 ml of dimethyl sulfoxide, and 2 ml of 30% hydrogen peroxide (the molar ratio to Formula 1 was 5) and potassium hydroxide aqueous solution (containing 14 g, 0.25 mol of potassium hydroxide) were added. The temperature was controlled at 65°C to 70°C and the reaction was carried out for 15 hours. After the reaction, the organic layer was washed with water, and the organic layer was taken, dried with sodium sulfate (5.0 g) and then spin-dried to obtain a white solid, which was slurried with ethyl acetate (40 ml) to obtain 1,1-diformamidocyclopropane with a yield of 96.3% and a purity of 99.44%.

[0088] Example 5

[0089] 1,1-dicyanocyclopropane (9.2 g, 0.1 mol) was dissolved in 185 ml of ethanol, and 1.3 ml of 30% hydrogen peroxide (the molar ratio with formula 1 was 1:8) and potassium carbonate aqueous solution (containing 41.5 g, 0.3 mol of potassium carbonate) were added. The temperature was controlled at 50°C to 55°C and the reaction was carried out for 16 hours. After the reaction, the organic layer was washed with water. The organic layer was taken, dried with sodium sulfate (5.0 g) and then spin-dried to obtain a white solid. The solid was slurried with ethyl acetate (40 ml) to obtain 1,1-diformamidocyclopropane with a yield of 94.3% and a purity of 99.33%.

[0090] Example 6

[0091] 1,1-Dicyanocyclopropane (9.2 g, 0.1 mol) was dissolved in 92 ml of tetrahydrofuran, and 10 ml of 30% hydrogen peroxide (with a molar ratio of 1:1 to Formula 1) and an aqueous sodium hydroxide solution (containing 4.0 g of sodium hydroxide, 0.1 mol) were added. The temperature was controlled at 25°C to 30°C and the reaction was carried out for 18 hours. After the reaction, the organic layer was washed with water, and the organic layer was taken, dried with sodium sulfate (5.0 g) and then spin-dried to obtain a white solid, which was slurried with ethyl acetate (40 ml) to obtain 1,1-diformamidocyclopropane with a yield of 93.8% and a purity of 99.54%.

[0092] (II) Preparation of N-(4-fluorophenyl)-1,1-dicarboxamide cyclopropane (IV)

[0093]

[0094] Example 7

[0095] 1,1-Dicarboxamidocyclopropane (12.8 g, 0.1 mol) and p-fluorophenylboronic acid (12.6 g, 0.09 mol) were dissolved in 465 ml methanol (8 times the total mass of the input materials), and potassium carbonate (27.6 g, twice the mole of Formula II) and Cu(OAc)2·H2O (5.1 g, 40% of the mass of Formula II) were added in sequence. The reaction system was heated to reflux for 8 hours. After the reaction was completed, it was cooled to room temperature, 120 ml of purified water was added, and then extracted with 200 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phases were combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (500 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamidocyclopropane with a yield of 96.5% and a purity of 99.7%.

[0096] Example 8

[0097] 1,1-Dicarboxamidocyclopropane (12.8 g, 0.1 mol) and p-fluorophenylboronic acid (14.0 g, 0.1 mol) were dissolved in 710 ml of dichloromethane (10 times the total mass of the input material), and pyridine (31.6 g, 4 times the mole of Formula II) and CuI (12.8 g, 100% of the mass of Formula II) were added in sequence. The reaction system was heated to reflux for 4 hours. After the reaction was completed, it was cooled to room temperature, 130 ml of purified water was added, and then extracted with 220 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (550 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamidocyclopropane with a yield of 95.6% and a purity of 99.3%.

[0098] Example 9

[0099] 1,1-Dicarboxamidocyclopropane (12.8 g, 0.1 mol) and p-fluorophenylboronic acid (11.2 g, 0.08 mol) were dissolved in 180 ml of acetonitrile (5 times the total mass of the input material), and triethylamine (10.1 g, 1 times the mole of Formula II) and Cu2O (1.3 g, 10% of the mass of Formula II) were added in sequence. The reaction system was heated to reflux for 11 hours. After the reaction was completed, it was cooled to room temperature, 100 ml of purified water was added, and then extracted with 100 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (480 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamidocyclopropane with a yield of 96.2% and a purity of 98.8%.

[0100] Example 10

[0101] 1,1-Dicarboxamidocyclopropane (12.8 g, 0.1 mol) and p-fluorophenylamine (10.0 g, 0.09 mol) acid were dissolved in 225 ml dimethylformamide (8 times the total mass of the input material), and Fe(NO3)3·9H2O (5.1 g, 40% of the mass of formula II) was added. The reaction system was heated to reflux for 8 hours. After the reaction was completed, it was cooled to room temperature, 100 ml of purified water was added, and then extracted with 100 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (450 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamidocyclopropane with a yield of 96.3% and a purity of 98.5%.

[0102] Embodiment 11

[0103] 1,1-Diformylaminocyclopropane (12.8 g, 0.1 mol) and p-fluorophenylamine (11.1 g, 0.1 mol) acid were dissolved in 370 ml toluene (10 times the total mass of the input material), and FeCl3·6H2O (12.8 g, 100% of the mass of Formula II) was added. The reaction system was heated to reflux for 4 h. After the reaction was completed, it was cooled to room temperature, 100 ml of purified water was added, and then extracted with 110 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness and then washed with a mixture of isopropanol and tetrahydrofuran (480 ml, the volume ratio of isopropanol to tetrahydrofuran was

[0104] 3:1) slurry, suction filtration and drying to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamide cyclopropane with a yield of 96.0% and a purity of 98.6%.

[0105] Example 12

[0106] 1,1-Diformylaminocyclopropane (12.8 g, 0.1 mol) and p-fluorophenylamine (8.9 g, 0.08 mol) acid were dissolved in 115 ml of dimethyl sulfoxide (5 times the total mass of the input material), and Fe2(SO4)3 (1.3 g, 10% of the mass of formula II) was added. The reaction system was heated to reflux for 12 hours. After the reaction was completed, it was cooled to room temperature, 100 ml of purified water was added, and then extracted with 100 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (450 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-diformylaminocyclopropane with a yield of 95.3% and a purity of 97.6%.

[0107] Example 13

[0108] 1,1-Diformylaminocyclopropane (12.8 g, 0.1 mol) and p-bromofluorobenzene (15.8 g, 0.09 mol) were dissolved in 600 ml toluene (8 times the total mass of the input material), and potassium carbonate (41.4 g, 3 times the mole of Formula II) and CuSO4·5H2O (5.1 g, 40% of the mass of Formula II) were added in sequence. The reaction system was heated to reflux for 12 hours. After the reaction was completed, it was cooled to room temperature, 110 ml of purified water was added, and then extracted with 200 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (480 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-diformylaminocyclopropane with a yield of 96.7% and a purity of 98.8%.

[0109] Embodiment 14

[0110] 1,1-Dicarboxamidocyclopropane (12.8 g, 0.1 mol) and p-chlorofluorobenzene (13.1 g, 0.1 mol) acid were dissolved in 600 ml dimethylformamide (9 times the total mass of the input material), and cesium carbonate (32.6 g, 1 times the mole of formula II) and Cu2O (7.7 g, 60% of the mass of formula II) were added in sequence. The reaction system was heated to reflux reaction for 8 hours. After the reaction was completed, it was cooled to room temperature, 110 ml of purified water was added, and then extracted with 200 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixed solution of isopropanol and tetrahydrofuran (700 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamidocyclopropane with a yield of 94.7% and a purity of 98.8%.

[0111] Embodiment 15

[0112] 1,1-Dicarboxamidocyclopropane (12.8 g, 0.1 mol) and p-fluoroiodobenzene (22.2 g, 0.1 mol) acid were dissolved in 320 ml dimethylformamide (5 times the total mass of the input material), and sodium carbonate (21.2 g, 2 times the mole of formula II) and Cu / SiO2 (5.1 g, 40% of the mass of formula II) were added in sequence. The reaction system was heated to reflux for 16 hours. After the reaction was completed, it was cooled to room temperature, 100 ml of purified water was added, and then extracted with 120 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and suspended to dryness, and then slurried with a mixture of isopropanol and tetrahydrofuran (700 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product N-(4-fluorophenyl)-1,1-dicarboxamidocyclopropane with a yield of 95.1% and a purity of 98.4%.

[0113] (III) Preparation of 4-((6,7-dimethyl-quinolin-4-yl)oxy)substituted benzene (V)

[0114]

[0115] Example 16: Preparation of 4-((6,7-dimethyl-quinolin-4-yl)oxy)aminobenzene

[0116]

[0117] 900 ml of N, N-dimethylformamide, 4-chloro-6,7-dimethoxyquinoline (22.4 g, 0.1 mol), p-aminophenol (10.9 g, 0.1 mol), and cesium carbonate (65.2 g, 0.2 mol) were added to a three-necked flask in sequence. The temperature was raised to 140°C and the reaction was continued for 8 hours. After the reaction was completed, the reaction solution was cooled and poured into 2.5 L of saturated sodium chloride aqueous solution. The solution was slurried with 1.8 L of ethyl acetate and filtered. The solution was dried to obtain 4-((6,7-dimethyl-quinolin-4-yl)oxy)aminobenzene with a yield of 95.6% and a purity of 98.4%.

[0118] Example 17: Preparation of 4-((6,7-dimethyl-quinolin-4-yl)oxy)phenylboronic acid

[0119]

[0120] Add 900ml of dimethyl sulfoxide, 4-bromo-6,7-dimethoxyquinoline (26.8g, 0.1mol), p-hydroxyphenylboric acid (27.6g, 0.2mol), and sodium methoxide (32.4g, 0.6mol) in a three-necked flask. Heat to 160°C and react for 10 hours. After the reaction is completed, cool the reaction solution, pour it into 1.5L saturated aqueous ammonium chloride solution, slurry it with 1.8L butyl acetate, filter it, and dry it to obtain 4-((6,7-dimethyl-quinolin-4-yl)oxy)phenylboric acid with a yield of 96.2% and a purity of 98.2%.

[0121] Example 18: Preparation of 4-((6,7-dimethyl-quinolin-4-yl)oxy)chlorobenzene

[0122]

[0123] Add 900ml chlorobenzene, 4-bromo-6,7-dimethoxyquinoline (26.8g, 0.1mol), 4-chlorophenol (19.3g, 0.15mol), and sodium hydroxide aqueous solution (containing 16.0g, 0.4mol of sodium hydroxide) in a three-necked flask. Heat to 80°C and react for 5 hours. After the reaction is completed, cool the reaction solution, pour it into 1.5L saturated aqueous ammonium chloride solution, slurry it with 1.8L isopropyl acetate, filter it, and dry it to obtain 4-((6,7-dimethyl-quinolin-4-yl)oxy)chlorobenzene, with a yield of 94.2% and a purity of 97.5%.

[0124] (IV) Preparation of Catinib

[0125] Embodiment 19

[0126]

[0127] N-(4-fluorophenyl)-1,1-dicarboxamide cyclopropane (19.0 g, 0.1 mol) and 4-((6,7-dimethyl-quinolin-4-yl)oxy)phenylboronic acid (29.2 g, 0.09 mol) were dissolved in 700 ml methanol (8 times the total mass), and potassium carbonate (27.6 g, 0.2 mol) and Cu(OAc)2·H2O (7.6 g, 40% of the mass of formula IV) were added in sequence. The reaction system was heated to reflux for 10 h. After the reaction was completed, it was cooled to room temperature, 150 ml of purified water was added, and then extracted with 200 ml of ethyl acetate. The extraction was repeated three times. The ethyl acetate phase was combined and dried, and then slurried with a mixture of isopropanol and tetrahydrofuran (1000 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product cabozantinib with a yield of 98.8% and a purity of 99.7%. .

[0128] Implementation Case 20:

[0129]

[0130] N-(4-fluorophenyl)-1,1-dicarboxamide cyclopropane (19.0 g, 0.1 mol) and 4-((6,7-dimethyl-quinolin-4-yl)oxy)aminobenzene (29.6 g, 0.1 mol) were dissolved in 500 ml dimethylformamide (10 times the total mass), and Fe(NO3)3·9H2O (1.9 g, 10% of the mass of formula IV) was added. The reaction system was heated to reflux reaction for 8 hours, and after the reaction was completed, it was cooled to room temperature, 130 ml of purified water was added, and then extracted with 200 ml of ethyl acetate, and the extraction was repeated three times. The ethyl acetate phase was combined and dried, and then slurried with a mixture of isopropanol and tetrahydrofuran (1000 ml, the volume ratio of isopropanol to tetrahydrofuran was 3:1), filtered, and dried to obtain the product cabozantinib, with a yield of 98.5% and a purity of 99.4%.

[0131] Embodiment 21

[0132]

[0133] N-(4-fluorophenyl)-1,1-dicarboxamide cyclopropane (19.0 g, 0.1 mol) and 4-((6,7-dimethyl-quinolin-4-yl)oxy)aminobenzene (27.8 g, 0.08 mol) were dissolved in 350 ml of dimethyl sulfoxide (5 times the total mass), and Cu / SiO2 (19.0 g, 100% of the mass of formula IV) was added. Reflux reaction for 15 hours, after the reaction is completed, cool to room temperature, add 100 ml of purified water, and then extract with 150 ml of ethyl acetate, repeat the extraction three times, combine the ethyl acetate phase and spin dry, then slurry with a mixture of isopropanol and tetrahydrofuran (1000 ml, isopropanol and tetrahydrofuran volume ratio of 3:1), filter, and dry to obtain the product cabozantinib, with a yield of 98.6% and a purity of 99.3%.

Claims

1. A method for synthesizing cabozantinib, characterized in that: The compound of formula VI is obtained by reacting the compound of formula IV with the compound of formula V. The synthesis route is as follows: Wherein R is Cl, Br, I, NH2 or B(OH)2.

2. The method for synthesizing cabozantinib according to claim 1, wherein The specific steps include: The compound of formula V, 4-((6,7-dimethyl-quinolin-4-yl)oxy)substituted benzene and the compound of formula IV, N-p-fluorophenyl-1,1-dicarboxamidocyclopropane, are dissolved in an organic solvent, and then a base and a catalyst are added in sequence, and the mixture is heated under reflux for reaction. After the reaction is completed, post-treatment is performed to obtain the compound of formula VI, cabozantinib.

3. The method for synthesizing cabozantinib according to claim 2, wherein: The molar ratio of the compound of formula V to the compound of formula IV is 1:0.8 to 1:

1.

4. The method for synthesizing cabozantinib according to claim 2, wherein: The mass of the catalyst used is 10% to 100% of the mass of the compound of formula V; the molar amount of the base used is 1 to 4 times the molar amount of the compound of formula V; the volume amount of the organic solvent used is 5 to 10 times the total mass of the input materials of the compound of formula V, the compound of formula IV, the base and the catalyst, where the volume is measured in ml and the mass is measured in g.

5. The method for synthesizing cabozantinib according to claim 1, wherein: The compound of formula IV is obtained by the following reaction: wherein R is as defined in claim 1.

6. The method for synthesizing cabozantinib according to claim 5, characterized in that: The compound of formula IV is prepared specifically by the following method: The compound 1,1-dicarboxamidocyclopropane of formula II and the substituted fluorobenzene of formula III are dissolved in an organic solvent, and then a base and a catalyst are added in sequence, and the mixture is heated under reflux for reaction. After the reaction is completed, post-treatment is performed to obtain the compound N-p-fluorophenyl-1,1-dicarboxamidocyclopropane of formula IV.

7. The method for synthesizing cabozantinib according to claim 6, wherein: The molar ratio of the compound of formula II to the compound of formula III is 1:0.8 to 1:

1.

8. The method for synthesizing cabozantinib according to claim 6, wherein: The mass of the catalyst used is 10% to 100% of the mass of the compound of formula II; the molar amount of the base used is 1 to 4 times the molar amount of the compound of formula II; the volume amount of the organic solvent used is 5 to 10 times the total mass of the compound of formula II, the compound of formula III, the base and the catalyst, where the volume is measured in ml and the mass is measured in g.

9. The method for synthesizing cabozantinib according to claim 5, characterized in that: The compound of formula II is obtained by hydrolyzing the compound of formula I in a hydrolysis system: 。 10. A method for synthesizing cabozantinib, characterized in that The synthetic route is as follows: Wherein, R is Cl, Br, I, NH2 or B(OH)2.

Citation Information

Cited By

  • Synthesis method of cabozantinib

    CN121974847A